Patient characteristics
| Characteristic | TNFi use | No TNFi use |
| No of patients | 15 598 | 73 839 |
| JIA | 7419 (48%) | 23 116 (31%) |
| pIBD | 6808 (44%) | 20 049 (27%) |
| pPsO | 1371 (9%) | 30 674 (42%) |
| Female | 57% | 57% |
| Race | ||
| White | 21% | 33% |
| Black | 7% | 10% |
| Other/unknown | 72% | 57% |
| MAX data source (%) | 41 | 61 |
| Mean age in years at start of follow-up (SD) | 13.4 (4.2) | 11.6 (4.7) |
| Median age in years at start of follow-up (IQR) | 14.0 (11.0–17.0) | 12.0 (8.0–16.0) |
| Mean years of follow-up (SD) | 2.0 (1.8) | 1.7 (1.7) |
| Median years of follow-up (IQR) | 1.4 (0.6–2.8) | 1.1 (0.4–2.3) |
5959 patients contributed to both no TNFi use and then subsequently the TNFi use cohorts.
JIA, juvenile idiopathic arthritis; MAX, Medicaid Analytic eXtract; pIBD, paediatric inflammatory bowel disease; pPsO, paediatric plaque psoriasis; TNFi, tumour necrosis factor inhibitor.